Veradigm ends strategic review after no firm bids
Seeking Alpha News (Thu, 30-Jan 5:36 PM ET)
McKesson declares $0.71 dividend
Seeking Alpha News (Thu, 30-Jan 8:18 AM ET)
McKesson Corporation Declares Quarterly Dividend
Business Wire (Thu, 30-Jan 8:00 AM ET)
Evercore ISI Sticks to Its Buy Rating for McKesson (MCK)
TipRanks (Tue, 28-Jan 2:16 AM ET)
McKesson Corporation Completes Divestiture of Canada-Based Rexall and Well.ca Businesses
Business Wire (Tue, 31-Dec 8:00 AM ET)
Business Wire (Mon, 30-Dec 8:00 AM ET)
Business Wire (Wed, 6-Nov 4:10 PM ET)
Bullish On MCK? You Might Want To Consider This Credit Put Spread Expiring in 6 Days
Market Chameleon (Fri, 2-Aug 9:12 AM ET)
McKesson Corp is one of three leading pharmaceutical wholesalers in the us engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the us pharmaceutical wholesale industry. Outside the us market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Mckesson trades on the NYSE stock market under the symbol MCK.
As of January 31, 2025, MCK stock price declined to $597.38 with 85,509 million shares trading.
MCK has a beta of 0.95, meaning it tends to be less sensitive to market movements. MCK has a correlation of 0.17 to the broad based SPY ETF.
MCK has a market cap of $75.83 billion. This is considered a Large Cap stock.
Last quarter Mckesson reported $94 billion in Revenue and $7.07 earnings per share. This beat revenue expectation by $4 billion and exceeded earnings estimates by $.19.
In the last 3 years, MCK traded as high as $637.51 and as low as $252.61.
The top ETF exchange traded funds that MCK belongs to (by Net Assets): VTI, VOO, SPY, IVV, VTV.
MCK has underperformed the market in the last year with a price return of +22.5% while the SPY ETF gained +25.6%. However, in the short term, MCK had mixed performance relative to the market. It has outperformed in the last 3 months, returning +19.8% vs +5.4% return in SPY. But in the last 2 weeks, MCK shares have been beat by the market, returning +0.4% compared to an SPY return of +3.0%.
MCK support price is $596.67 and resistance is $612.54 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MCK shares will trade within this expected range on the day.